Related Experiment Videos
Refractory/therapy-resistant/intractable constipation in children
Carlos Alberto Velasco-Benítez1, Wilson Daza Carreño2, Michelle Higuera Carrillo3
1Hospital Universitario del Valle, Universidad del Valle, Cali, Valle del Cauca, Colombia.
Introduction:
A better understanding of key concepts is required to properly characterise intractable constipation (IC). We aimed to determine how IC is defined by Latin and Ibero-American paediatric gastroenterologists.
Methods:
A questionnaire was administered to evaluate concepts supporting the definition and use of a unified term for IC. The collected data were analysed using univariate and bivariate analyses. ORs with their corresponding 95% CIs were calculated, p values <0.05 were statistically significant.
Results:
A total of 429 paediatric gastroenterologists participated: 45.7% Latin American Society for Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN) members (group 1), 16.3% Ibero-American LASPGHAN members (group 2) and 38.0% non-LASPGHAN affiliates (group 3). Most respondents considered lower bowel frequency despite receiving 'optimal medical treatment' (94.6%), with 51.0% indicating a period of 2-3 months; defined 'prior treatment failure' as the use of two laxatives (51.7%); selecting the tertiary level care prior to diagnosis (43.1%); wished to include the term 'optimal medical treatment' for diagnostic criteria (93.0%); believed follow-up should be carried out by a paediatrician/specialist (86.7%) and preferred the term refractory constipation (86.7%). When comparing group 1 versus group 2, the Spanish group preferred the term 'treatment-resistant constipation' (OR=1.96; 95% CI 1.08 to 3.55; p=0.0157).
Conclusions:
Latin and Ibero-American paediatric gastroenterologists prefer replacing the term 'IC' with 'refractory/treatment-resistant constipation' defined as a form of paediatric FC characterised by the persistence of clinically relevant symptoms despite optimal conventional medical treatment, appropriately prescribed, supervised and adhered to for a minimum period of 2-3 months, after structural, neurological and metabolic organic causes have been excluded.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Irritable Bowel Syndrome III: Medical and Nursing Management
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists